3 documents found, page 1 of 1
An HIV-1/HIV-2 Chimeric Envelope Glycoprotein Generates Binding and Neutralisin...
Taveira, Nuno; Figueiredo, Inês; Calado, Rita; Martin, Francisco; Bártolo, Inês; Marcelino, José M.; Borrego, Pedro; Cardoso, Fernando; Barroso, HelenaFunding Information: This work was funded by national funds through the FCT-Foundation for Science and Technology, I.P., under the project UIDB/04585/2020, by FCT and Aga Khan Development Network (AKDN)—Portugal Collaborative Research Network in Portuguese speaking countries in Africa, project 332821690 and by Ministry of Health, Portugal, project HIV/SAU/0008.11. Publisher Copyright: © 2023 by the authors.; Th...
Development of a Gold Nanoparticle-Based Lateral-Flow Immunoassay for Pneumocys...
Tomás, Ana Luísa; de Almeida, Miguel P.; Cardoso, Fernando; Pinto, Mafalda; Pereira, Eulália; Franco, Ricardo; Matos, OlgaUID/Multi/04378/2019. POCI-01-0145-FEDER-007728. UID/QUI/50006/2019. POCI-01-0145-FEDER-007265. SFRH/BD/108433/2015. GG/001/2014.; Pneumocystis jirovecii pneumonia (PcP) is a major human immunodeficiency virus (HIV)-related illness, rising among immunocompromised non-HIV patients and in developing countries. Presently, the diagnosis requires respiratory specimens obtained through invasive and costly techniques ...
Therapeutic potential of caspofungin combined with trimethoprim-sulfamethoxazol...
Lobo, ML; Esteves, Francisco Vaz de Carvalho; Sousa, Bruno Cecílio de; Cardoso, Fernando; Cushion, M.T.; Antunes, FranciscoPneumocystis pneumonia (PcP) is a major cause of mortality and morbidity in immunocompromised patients. There are limited alternative therapeutic choices to trimethoprim-sulfamethoxazole (TMP-SMX) which is the standard first line therapy/prophylaxis for PcP. The efficacy of low doses of caspofungin and caspofungin in association with TMP-SMX standard-prophylactic dose was evaluated in an experimental model of P...